Drug: |
||||
---|---|---|---|---|
Trial Name: |
Doxorubicin and Flavopiridol in Treating Patients With Metastatic or Recurrent Sarcoma That Cannot Be Removed By Surgery |
|||
NCT#: |
||||
Conditions: |
Gastrointestinal Stromal Tumor
Sarcoma |
|||
Status: |
Completed |
|||
Phase: |
1 |
Start Date 12/01/2004 |
Age of Trial (yrs) 18.8 |
|
Treatment Phase: |
Gleevec-resistant |
|||
Drug Category: |
Transcription inhibitor + Chemotherapy |
|||
Strategy: |
Freeze the cell division cycle |
|||
Trial Type: |
Specifically GIST plus other cancers |
|||
Other Protocol IDs: |
CDR0000398181, MSKCC-04075, NCI-6204 |
|||
Sponsor: |
Memorial Sloan-Kettering
NCI |
|||
Patient Contact: |
See site contact info below |
|||
Contact email: |
||||
Contact Phone: |
||||
Randomized: |
no |
|||
IV or Oral: |
IV
Intravenous |
|||
Trial Notes: |
This is a phase I trial to determine the maximum tolerated dose of the combination of doxorubicin (a traditional cytotoxic chemotherapy) with flavopiridol (an inhibitor of the cell cycle and an inhibitor of transcription). This trial is for sarcoma patients, including GIST patients, that are 18 years old or older. Patients must have a Performance status of ECOG 0-2 or Karnofsky 60-100%. Projected accrual is 3 to 36 patients. The trial is being conducted at Memorial Sloan-Kettering Cancer Center (MSKCC) in New York, N.Y. U.S.A. The principal investigator is Dr. David D’Adamo. |
Trial Links |
Trial Results |
Drug Information |
Doxorubicin - Wikipedia |
Doxorubincin - Chemocare.com |
Name |
Address |
City |
State |
Zip |
Country |
1275 York Ave |
New York |
NY |
10065 |
USA |